Navigation Links
Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge
Date:4/1/2015

PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of Daiichi Sankyo Company, Ltd, announced today that it will merge with its US-based sister company, Asubio Pharmaceuticals, Inc.  As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization, led by Mahmoud Ghazzi, MD, PhD.

Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research.

Asubio Pharmaceuticals, Inc.'s ongoing clinical trial in patients with acute spinal cord injury, ASBI 603ASCENT Study (SUN13837) has completed enrollment.  An analysis and dissemination of the data will be managed by Daiichi Sankyo. 

"In line with the Daiichi Sankyo five-year business plan to optimize our business of delivering innovative treatments to patients, consolidating the current Asubio US projects under the company's overall R&D organization helps us streamline our operations," said Glenn Gormley, MD, PhD, Senior Executive Officer and Global Head of R&D, Daiichi Sankyo Company, Ltd., and Executive Chairman and President, Daiichi Sankyo, Inc.

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, dyslipidemia and bacterial infections used by patients around the world, the Group has also launched treatments for thrombotic disorders and is building new product franchises. Furthermore, Daiichi Sankyo research and development is focused on bringing forth novel therapies in oncology and cardiovascular-metabolic diseases, including biologics. The Daiichi Sankyo Group has created a "Hybrid Business Model," to respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit www.dsi.com.


'/>"/>
SOURCE Daiichi Sankyo, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
4. Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics
5. Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
6. Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
7. Daiichi Sankyo to Acquire Ambit Biosciences
8. Daiichi Sankyo adquiere Ambit Biosciences
9. Daiichi Sankyo wird Ambit Biosciences übernehmen
10. Daiichi Sankyo va acquérir Ambit Biosciences
11. Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/11/2019)... , ... November 11, 2019 , ... Over 60 schools ... telehealth service in place. The program is designed to provide virtual mental health care ... storm that struck the region in October of 2018 [1]. , “This initiative by ...
(Date:11/11/2019)... , ... November 11, 2019 , ... The Naderi Center ... America health care practice POS, point of sale, website for providing the highest level ... Naderi Center for Cosmetic Surgery Specialists uses advanced financial technology in their daily business ...
(Date:11/11/2019)... ... ... The Advocator Group, LLC, part of Brown & Brown Inc., is honored ... the Boston Globe Magazine. This recognition has been earned for the fourth consecutive year ... , The rankings for the Top 100 Women-Led Businesses in each state are ...
Breaking Medicine Technology:
(Date:11/12/2019)... ... November 12, 2019 , ... ... study. With increasing site activation cycle times, extended contract negotiations and 80 percent ... an area of clinical operations that’s ripe for improvement. Following an overview of ...
(Date:11/11/2019)... IRVINE, Calif. (PRWEB) , ... November 11, 2019 ... ... providers of business support services to dental groups in the United States, today ... serving the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable ...
(Date:11/11/2019)... ... 11, 2019 , ... Dr. John V. Prunskis, co-founder and co-Medical Director of ... Pain Management Best Practices Task Force (Pain Task Force) met last Monday with Joe ... to the HHS Pain Task Force’s final report that was submitted to Congress in ...
(Date:11/9/2019)... YORK (PRWEB) , ... November 09, 2019 , ... On ... the story of a retired and disabled 64-year-old New Yorker who recently faced homelessness. ... moved her into transitional housing until she found a new home in an assisted-living ...
(Date:11/7/2019)... ... 07, 2019 , ... Understanding UDI in EU Device Regulations, An FDAnews Webinar, ... Are EU device and IV diagnostics sales in jeopardy? , It’s not a trick ... ahead, and many device and diagnostics makers simply aren’t prepared. , Not yet anyway. ...
Breaking Medicine News(10 mins):